Tag Archives: biopharmaceutical
Replicor publishes its REP 301-LTF study achieving durable functional cure of HDV and HBV, inactivation of cccDNA and elimination of integrated HBV DNA
Below, we are re-publishing with permission the press-release issued by Replicor Inc. on November 16, 2020 MONTREAL, November 16th, 2020 – Replicor Inc., a privately held biopharmaceutical company targeting functional cure for patients with chronic hepatitis B and D infection, … Continue reading
